Search
metreleptin (Myalepta)
Indications:
- generalized lipodystrophy (FDA-approved Feb 2014)
- leptin deficiency [3]
Contraindications:
- hypertriglyceridemia associated with diabetes mellitus
- HIV1-related lipodystrophy
- generalized obesity
Dosage:
- 11.3 mg powder for injectable solution
Adverse effects:
- hypoglycemia
- weight loss
- injection site reactions
- formation of neutralizing antibodies.
Mechanism of action:
- recombinant human leptin analog
- binds to & activates human leptin receptor
- decreases different types of fat in the body
- reduces fat accumulation in tissues, including liver & muscle
- lowers glycated hemoglobin & serum triglycerides in patients with lipodystrophy
General
metabolic agent (metabolic modifier)
recombinant protein; chimer
References
- Medscape: Feb 25, 2014
Myalept (Metreleptin) Approved for Generalized Lipodystrophy.
http://www.medscape.com/viewarticle/821056
- Chou K1, Perry CM.
Metreleptin: first global approval.
Drugs. 2013 Jun;73(9):989-97.
PMID: 23740412
- Brown T
EMA Panel Recommends Metreleptin for Leptin Deficiency.
Medscape - Jun 01, 2018.
https://www.medscape.com/viewarticle/897471